|Nome||Titolo||Retribuzione||Esercitate||Anno di nascita|
|Dr. Jeffrey Marc Leiden||Chairman, CEO & Pres||4,75M||19,14M||1956|
|Mr. Michael J. Parini||Exec. VP and Chief Legal & Admin. Officer||1,61M||3,28M||1975|
|Mr. Amit K. Sachdev||Exec. VP & Chief Patient Officer||1,16M||9,02M||1968|
|Mr. Stuart A. Arbuckle||Exec. VP & Chief Commercial Officer||1,59M||4,45M||1966|
|Mr. Charles F. Wagner Jr.||Exec. VP & CFO||N/D||N/D||1968|
Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for the treatment of cystic fibrosis. The company markets TRIKAFTA, SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene. It is also developing VX-814, which is in Phase 2 clinical trial and VX-864 that is in Phase 1 clinical trial for the treatment of alpha-1 antitrypsin deficiency; VX-147 for treating kidney diseases; and CTX001 that is in Phase 1/2 clinical trial for the treatment of beta-thalassemia and sickle cell diseases. In addition, the company develops VX-150, an inhibitor that is in Phase 2 clinical trial for acute, neuropathic, and musculoskeletal pain; and VX-561, a potentiator that is in Phase 2 clinical development; as well as evaluating VX-121, an additional corrector. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. Vertex Pharmaceuticals Incorporated has collaborations with CRISPR Therapeutics AG; Kymera Therapeutics; BioAxone Biosciences, Inc.; Parion Sciences, Inc.; Merck KGaA; Janssen Pharmaceuticals, Inc.; Arbor Biotechnologies, Inc.; Moderna Therapeutics, Inc.; Genomics plc; Darmstadt, Germany; X-Chem, Inc.; Ribometrix, Inc.; and Molecular Templates, Inc. The company was founded in 1989 and is headquartered in Boston, Massachusetts.
L'ISS Governance QualityScore di Vertex Pharmaceuticals Incorporated al 3 febbraio 2020 è 8. I criteri di valutazione fondamentali sono revisione: 2; Consiglio di Amministrazione: 9; diritti degli azionisti: 7; retribuzione: 8.